Descartes-11 / Cartesian Therapeutics - LARVOL DELTA

Descartes-11 in Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Terminated | Sponsor: Cartesian Therapeutics | Phase classification: P1/2 ➔ P1 | Active, not recruiting ➔ Terminated; Phase 1 enrollment completed. Further clinical development terminated.

Phase classification • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-11 in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=25 | Active, not recruiting | Sponsor: Cartesian Therapeutics | Trial completion date: Dec 2022 ➔ Feb 2024 | Trial primary completion date: Aug 2022 ➔ Feb 2024

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-11 in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=25 | Active, not recruiting | Sponsor: Cartesian Therapeutics | Completed ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Aug 2019 ➔ Aug 2022

Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-11 in Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=25 | Completed | Sponsor: Cartesian Therapeutics | Recruiting ➔ Completed | N=18 ➔ 25 | Trial completion date: Dec 2022 ➔ Dec 2021

Enrollment change • Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy (clinicaltrials.gov) - P2 | N=4 | Completed | Sponsor: Cartesian Therapeutics | Recruiting ➔ Completed | N=30 ➔ 4 | Trial completion date: Apr 2025 ➔ Mar 2022

Enrollment change • Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma (OncLive) - "'Patients [who are] newly diagnosed with high-risk multiple myeloma seldom achieve deep, durable responses after frontline therapy,' said Kenneth C. Anderson, MD...'Integrating a CAR T-cell therapy into our standard of care, without using lymphodepleting chemotherapy, would be a welcome addition to our toolkit for treating this currently incurable disease'....The estimated primary completion date is set for April 2022, with an estimated study completion date set for April 2025."

Media quote

Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer (PRNewswire) - P1/2, N=18; NCT03994705; Sponsor: Cartesian Therapeutics; "Cartesian Therapeutics...announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma...'Patients newly diagnosed with high-risk multiple myeloma seldom achieve deep, durable responses after frontline therapy,' said Kenneth Anderson, MD...A Phase 1 study of Descartes-11 in patients with advanced myeloma showed no evidence of typical CAR T-cell toxicities such as cytokine release syndrome (CRS) of neurotoxicity....The Phase 2a study (NCT04436029) is enrolling patients with newly diagnosed, high-risk multiple myeloma at multiple centers in the United States."

Cytokine release syndrome • P1 data • Trial status • Hematological Malignancies • Multiple Myeloma • Oncology